Trials / Completed
CompletedNCT05922891
Tezepelumab PRO Study
Effectiveness of Tezepelumab on Asthma Control and Cough: A Prospective, Multi-center, Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 92 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
This study assesses the impact of tezepelumab treatment not only on asthma control but also on cough specific Health-Related Quality of Life (HRQoL). Asthma control can be evaluated using Asthma Control Questionnaire (ACQ). Cough symptom which is one of the symptoms related airway hyperresponsiveness can be assessed via the relevant questionnaire, Leicester Cough Questionnaire (LCQ). There is moderate negative correlation between ACQ and LCQ . Improvements in both asthma control and cough symptom by tezepelumab would clarify effectiveness of Tezepelumab in real-world. Though Tezepelumab is recently approved in Japan, there is no real-world evidence on tezepelumab, particularly on above mentioned symptoms. Thus, this study aims to estimate effectiveness of tezepelumab on asthma and cough symptoms in real world settings.
Conditions
Timeline
- Start date
- 2023-09-27
- Primary completion
- 2025-09-20
- Completion
- 2025-09-20
- First posted
- 2023-06-28
- Last updated
- 2025-09-30
Locations
29 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT05922891. Inclusion in this directory is not an endorsement.